Geron (GERN) Current Assets (2010 - 2026)
Geron (GERN) posted Current Assets of $498.5 million for Q1 2026, down 4.18% sequentially from $520.3 million in Q4 2025, and up 0.56% YoY from $495.8 million in Q1 2025.
Geron (GERN) Current Assets (2010 - 2026) Analysis & Trends
Geron has reported Current Assets for 17 years, with the latest figure at $498.5 million in Q1 2026.
- Quarterly Current Assets rose 0.56% year-over-year to $498.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $498.5 million (up 0.56% YoY) and the FY2025 annual result came in at $520.3 million, up 5.96% from the prior year.
- Current Assets declined to $498.5 million in Q1 2026 per GERN's latest filing, from $520.3 million in the prior quarter.
- Over five years, Current Assets peaked at $522.3 million in Q3 2025 and troughed at $175.9 million in Q1 2022.
- A 5-year average of $382.5 million and a median of $387.0 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2023: Current Assets fell 18.28% in 2022, then soared 119.99% in 2023.
- Over 5 years, Current Assets stood at $180.2 million in 2022, then jumped by 89.38% to $341.3 million in 2023, then surged by 43.84% to $491.0 million in 2024, then increased by 5.96% to $520.3 million in 2025, then retreated by 4.18% to $498.5 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $498.5 million, $520.3 million, and $522.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | Geron | 1.04 Mn | -299.81 Mn | - | 486.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 486.34 Mn |
| Mar 31, 2026 | 498.53 Mn |
| Dec 31, 2025 | 520.27 Mn |
| Sep 30, 2025 | 522.34 Mn |
| Jun 30, 2025 | 505.60 Mn |
| Mar 31, 2025 | 495.77 Mn |
| Dec 31, 2024 | 490.99 Mn |
| Sep 30, 2024 | 398.06 Mn |
| Jun 30, 2024 | 373.31 Mn |
| Mar 31, 2024 | 451.51 Mn |
| Dec 31, 2023 | 341.35 Mn |
| Sep 30, 2023 | 335.09 Mn |
| Jun 30, 2023 | 377.28 Mn |
| Mar 31, 2023 | 387.02 Mn |
| Dec 31, 2022 | 180.25 Mn |
| Sep 30, 2022 | 222.07 Mn |
| Jun 30, 2022 | 227.38 Mn |
| Mar 31, 2022 | 175.92 Mn |
| Dec 31, 2021 | 187.21 Mn |
| Sep 30, 2021 | 179.36 Mn |